DYNAVAX TECHNOLOGIES CORPORATION MANAGEMENT CONTINUITY AND SEVERANCE AGREEMENT Amended October 3, 2008Management Continuity and Severance Agreement • March 6th, 2009 • Dynavax Technologies Corp • Pharmaceutical preparations • California
This Management Continuity and Severance Agreement (the “Agreement”) is dated as of [DATE], by and between [NAME OF EXECUTIVE OFFICER], [TITLE OF EXECUTIVE OFFICER], Dynavax Technologies Corporation (“Employee”), and Dynavax Technologies Corporation, a Delaware corporation (the “Company” or “Dynavax”).
RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT BETWEEN GLAXO GROUP LIMITED AND DYNAVAX TECHNOLOGIES CORPORATIONResearch and Development Collaboration and License Agreement • March 6th, 2009 • Dynavax Technologies Corp • Pharmaceutical preparations • Delaware
This RESEARCH AND DEVELOPMENT COLLABORATION AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of the 15th day of December, 2008 (the “Effective Date”) by and between Dynavax Technologies Corporation, a Delaware corporation having its principal place of business at 2929 Seventh Street, Suite 100, Berkeley, CA 94710 (“Dynavax”), and Glaxo Group Limited, a company existing under the laws of England and Wales, having its registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex, UB6 0NN, England (“GSK”). Dynavax and GSK are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
